R Discovery

Overview

RDiscovery is a Japan-US cross-border venture capital firm focused on identifying and developing early-stage biotechnology discoveries. It invests in and develops technologies and companies that drive innovation in therapeutic development, particularly those originating from Japanese academic institutions.

Key Features

• Cross-border Venture Capital — RDiscovery operates as a Japan-US cross-border venture capital firm, leveraging a global network.
• Early-Stage Biotechnology Focus — The firm identifies and invests in early-stage biotechnology discoveries.
• Therapeutic Development — RDiscovery focuses on technologies and companies that advance therapeutic development.
• In-house Incubator — An in-house incubator, operated by their team, supports the creation and scaling of companies.
• Japan-Origin Innovation — The RDiscovery Fund is dedicated to fostering innovation originating from leading Japanese academic institutions.
• Company Building — RDiscovery acts as entrepreneurs to build companies around promising pharmaceutical assets.
• Board Governance Contribution — The firm serves as venture partners and contributes to strong board governance.

Who It's For

RDiscovery is for early-stage biotechnology companies and academic institutions in Japan seeking capital, development support, and global market access for their therapeutic innovations. It targets founders and researchers with promising preclinical-stage assets in life sciences, aiming to translate them into clinical-stage therapies.

Notable Strengths

RDiscovery's primary strength lies in its unique Japan-US cross-border model, specifically targeting and de-risking early-stage Japanese biotech assets for the global market. The firm's in-house incubator and venture team provide hands-on support, including financial, biotech, and translational expertise, to build and scale companies from academic discoveries. This approach aims to address unmet patient needs globally by leveraging Japan's significant contribution to new drug approvals.